BioSpace News Archive

Pfizer Inc. announced the pricing of a debt offering consisting of five tranches of notes:

Adhera Therapeutics (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, and Alyvant, a company focused on tech-enabled pharma commercialization, today announced a digital co-promotion agreement for Prestalia®, an approved therapy for the treatment of hypertension.

Current Deciphera Director and Experienced Commercial Oncology Executive, Steve Hoerter, Appointed as New President & Chief Executive Officer

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced positive top-line results from the phase 3 heiGHt Trial, a randomized, open-label, active-controlled trial that compared once-weekly TransCon Growth Hormone (hGH) to a daily growth hormone (Genotropin®) in children with pediatric growth hormone deficiency (GHD)

Offering proceeds, along with balance sheet cash, expected to fund a debt reduction of ~$550 million

Assistance for UnitedHealthcare plan participants whose access to care or prescriptions needs may have been affected

Suburban United Way joins Greater Chicago organization to increase community impact in the North-Northwest region

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences:

Stealth BioTherapeutics announced that it has issued an additional 588,232 American Depositary Shares at the public offering price of $12.00 per ADS, resulting in additional gross proceeds of approximately $7.1 million, pursuant to the exercise in part of the underwriters’ over-allotment option in connection with Stealth’s previously announced initial public offering of ADSs.

Dicerna Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.